HODGES STEPHEN,HODGES STEPHEN,SOPER ROBIN,SOPER ROBIN
申请号：
PL10801459
公开号：
PL2536398T3
申请日:
2010.12.22
申请国别(地区):
PL
年份:
2016
代理人:
摘要：
A compound of formula (I), or a pharmaceutically acceptable salt, tautomer or prodrug thereof, for use in the treatment of osteoporosis and/or osteopenia. R1or R2represents hydrogen, halogen, cyano, trifluoromethyl, nitro, ORa, SRa, SORa, SO2Ra, SO2NRa, SO2NRaRb, NRaRb, NRaCORb, NRaCO2Rb, CORa, CO2Ra, CONRaRb, Ak or Het. n = 1-4. R3represents a hydrocarbon group comprising a straight chain, branched or cyclic group each containing a to 18 carbon atoms, and being substituted by at least one moiety including a CO2Rasubstituent. Raand Rbindependently represent hydrogen, Ak or Het. Ak represents a hydrocarbon group comprising a straight chain, branched or cyclic group each containing u to 18 carbon atoms. Het represents a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom. Preferred are (4E)-6-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)-4-methylhex-4-enoic acid (2E)-6-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)-2-methylbut-2-enoic acid 8-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)octanoic acid. A composition comprising a compound of formula (I) and optionally a coagulant, preferably vitamin K, for use in the treatment of osteoporosis and/or osteopenia. A combination of a compound of formula (I) with a coagulant is also claimed per se. The aforementioned composition and combination may further include one or more of vitamins, minerals, a biphosphonate drug, teriparatide, strontium ranelate or oestrogen replacement therapy.
